Home
About Us
Information & Guidelines
Article Processing Charges
Open Access Policy
Terms and Conditions
Privacy Policy
User Feedback
Information For Authors
Information Editorial Board
Contact Us
FAQ
Paper Submission Guideline
Register
Login
Submit Now
Vol - 25, Issue - 8
Full-Text PDF
About the Journal
Download
[This article belongs to Volume - 25, Issue - 8]
International Medical Journal
Journal ID
:
IMJ-20-07-2020-542
Total View
:
327
Title
:
Rifaximin in hepatic encephalopathy: A review of the literature
Abstract
: Hepatic encephalopathy (HE) is a serious complication of liver cirrhosis with a great socioeconomic impact, which impairs the quality of life of patients. Non-absorbable disaccharides and rifaximin are the most commonly used treatments along with the correction of precipitating factors. There are few randomized-controlled trials and many of the current treatment recommendations are based on clinical practice. Rifaximin should start during an episode of HE if there is no clinical improvement after 24-48 hours of non-absorbable disaccharides therapy. Rifaximin as an add-on therapy to lactulose is prudent in recurrent HE in patients who develop a new episode. Rifaximin has proven an effective treatment option for overt HE and in the prevention of recurrence
Download Info
×
Paper Access Key
Access Key
Submit
No Access Key (
Request for Download
)
Name
Email
Country
Send Request
Our Certificates
Guidelines
Information For Authors
Information Editorial Board
FAQ
Further Information
Article Processing Charges
Open Access Policy
Terms and Conditions
Privacy Policy
User Feedback